Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

Company at a glance

• Nevada corporation headquartered in the South San Francisco area.
• Late clinical-stage therapeutics company developing intranasal pherine medicines and related programs for psychiatric and neurological disorders.
• Core technology: intranasal pherine compounds intended to rapidly and selectively activate nose-to-brain neurocircuits without requiring systemic absorption into the brain.
• Operations rely on a network of contract manufacturers and CROs.

What the company does

• Develops intranasal pherine product candidates across a neuroscience pipeline to address unmet medical needs in:
  • Social anxiety disorder (SAD)
  • Major depressive disorder (MDD)
  • Menopausal vasomotor symptoms (hot flashes)
  • Psychomotor impairment due to mental fatigue
  • Cancer cachexia
• Five clinical-stage intranasal pherine candidates:
  • Fasedienol (SAD)
  • Itruvone (MDD)
  • Refisolone (VMS/hot flashes)
  • PH15 (mental fatigue–related cognitive/psychomotor impairment)
  • PH284 (cancer cachexia)
• Also developing AV-101, an oral prodrug targeting NMDAR-related disorders, outside the intranasal pherine platform.

Pipeline and development status

• Fasedienol — acute treatment of SAD
  • U.S. Phase 3 program (PALISADE) with multiple trials: PALISADE-1, PALISADE-2, PALISADE-3, PALISADE-4, plus a Repeat Dose Study and open-label extensions.
  • Key clinical results:
    • PALISADE-1: topline results did not meet the primary endpoint.
    • PALISADE-2: topline results announced in August 2023 as meeting the primary endpoint.
    • PALISADE-3: randomized portion completed in December 2025 and did not meet the primary endpoint.
    • PALISADE-4: topline results were expected in Q2 2026.
    • Repeat Dose Study: randomized portion topline expected in Q3 2026.
    • Real-world open-label extension (OLE) data ongoing for PALISADE-3, PALISADE-4, and the Repeat Dose Study.
  • The company is in ongoing dialogue with the FDA and plans to seek feedback on NDA timing and the path forward.
• Itruvone (MDD)
  • Intranasal pherine candidate with FDA Fast Track designation.
  • Exploratory Phase 2A results in Mexico showed reductions in depressive symptoms.
  • U.S. IND opened; planning U.S. Phase 2 development.
• Refisolone (VMS/hot flashes)
  • Non-hormonal, non-systemic intranasal pherine candidate.
  • Phase 2A exploratory study in Mexico showed reduction in daily hot flashes versus placebo.
  • U.S. IND open for Phase 2 development; FDA issued a “Study May Proceed” letter in April 2026 for U.S. Phase 2 development.
  • Exclusive negotiations with Fuji Pharma (Japan) for a potential exclusive license; Fuji paid $1.5 million (non-refundable) as part of the Exclusive Negotiation Period.
• PH15 (mental fatigue–related cognitive/psychomotor impairment)
  • Phase 2A crossover data in Mexico showed improved reaction time and reduced errors versus placebo and caffeine.
  • Company evaluating next development steps and U.S. IND readiness.
• PH284 (cancer cachexia)
  • Targets appetite and mood-related neurocircuitry.
  • Phase 2A exploratory study in Mexico suggested a cumulative effect on Subjective Feeling of Hunger with no unusual adverse events reported.
• AV-101 (oral prodrug; NMDAR pathway)
  • Targets NMDAR-related neurological disorders, including depression, LID, and neuropathic pain.
  • FDA has granted Fast Track designations for AV-101 in certain indications.

Intellectual property

• Portfolio includes granted U.S. patents and foreign filings covering:
  • Use of fasedienol for SAD
  • Use of itruvone for MDD
  • Use of refisolone for VMS and migraines
  • Use of PH15 for mental fatigue
  • Use of PH284 for cancer cachexia
  • AV-101 for depression, LID, neuropathic pain, and related indications
  • Nasal spray devices for pherine administration
  • Manufacturing processes for AV-101
• Patent terms referenced for various assets (examples: 2025–2028 for fasedienol in certain jurisdictions; 2033–2045 for other products), with potential for regulatory data and patent term extensions under Hatch-Waxman.
• Regulatory exclusivities (e.g., U.S. new chemical entity and new clinical investigation exclusivities) and pediatric exclusivities may apply if corresponding data are submitted.
• Bayh-Dole rights may apply to inventions arising from U.S. government funding, if any.

Manufacturing and supply

• All pherine drug substances and drug products are manufactured by contract development and manufacturing organizations (CDMOs).
• Manufacturing is performed on a purchase/work order basis; the company does not maintain internal manufacturing facilities.
• Plans to negotiate long-term commercial supply agreements if products are approved.
• Clinical development supported by non-exclusive CRO arrangements.

Partnerships and strategic transactions

• AffaMed Therapeutics (formerly EverInsight): exclusive license for fasedienol in Greater China, Korea, and Southeast Asia.
  • Upfront payment: $5.0 million (August 2020).
  • Potential milestones and royalties on net sales in the Territory.
  • Term and scope governed by jurisdiction-by-jurisdiction expiration tied to last valid claim, regulatory exclusivity, or 10 years after first commercial sale.
• Fuji Pharma Co., Ltd.: Exclusive Negotiation Agreement (September 1, 2023) for a potential exclusive license of refisolone in Japan.
  • Fuji paid $1.5 million (non-refundable) for the exclusive negotiation period; if a definitive agreement is reached, the fee is creditable against upfront fees.
  • Exclusive negotiation period extends to the later of 14 months from the Payment Event or 90 days after FDA IND acceptance.

Commercialization and market considerations

• The company aims to develop and potentially commercialize multiple pherine products, either alone or with partners, in U.S. and international markets.
• Commercialization depends on regulatory approvals, coverage and reimbursement, and building sales and distribution capabilities in-house or via partners.
• The business plan contemplates substantial investment in late-stage development, regulatory submissions, and commercialization, which may be funded through equity, debt, collaborations, licensing, or other financing.

Financial snapshot

• Employees: 41 full-time employees as of March 31, 2026 (30 in R&D; 11 in management, corporate development, legal, HR, and other admin).
• Cash and equivalents: $45.4 million as of March 31, 2026; $80.5 million as of March 31, 2025.
• Net losses: $69.7 million for the year ended March 31, 2026; $51.4 million for the year ended March 31, 2025.
• Revenue: no product revenue reported; the company is not profitable and has historically operated at a loss.
• Going concern: as of June 15, 2026, there was substantial doubt about the company’s ability to continue as a going concern based on liquidity and funding considerations.
• Cash runway and capital needs: the company expects to require substantial additional financing to advance development, regulatory submissions, and potential commercialization; potential sources include equity, debt, collaborations, licensing, or royalty-based financing, which could dilute existing stockholders or impose restrictive covenants.
• Workforce adjustments: in March 2026 the board authorized an approximate 20% headcount reduction to preserve cash and focus on the PALISADE program; a retention package including new stock options was provided in April 2026.

People and governance

• The company relies on a network of CROs, CDMOs, and external consultants to support research, development, regulatory, manufacturing, and commercialization activities.
• Retention stock option awards were issued following the workforce reduction to retain remaining employees.

Summary takeaway

Vistagen is a late-stage biotech focused on intranasal pherine therapies, with five clinical intranasal candidates and AV-101 in the broader neuroscience portfolio. The company has an active U.S. Phase 3 SAD program (PALISADE) with mixed topline results to date, open INDs and Phase 2 paths for several candidates, and active licensing discussions with AffaMed and Fuji Pharma. The company has not generated product revenue, maintains a defined cash position, and expects to raise additional capital as it advances late-stage trials and potential regulatory submissions.